| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62f941494409aea84f621977c5f0ab81 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16334 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0021 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| filingDate |
2014-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9217d3a1c8adcd30383973a4c9a3bfbc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_643d3c5acfb20658915c1763646cbbf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c316257ff7080a31772a8110117c30b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f78cb878c8d02c3f888d160b34a1c88 |
| publicationDate |
2016-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2016220483-A1 |
| titleOfInvention |
Thermally Stable Vaccine Formulations and Microneedles |
| abstract |
Formulations and methods are provided for stabilizing antigens in dry solid vaccines. One aspect relates to dry solid formulations of influenza vaccines including one or more excipients identified as imparting stability to influenza antigens. Another aspect relates to dry solid formulations of measles vaccines including one or more excipients identified as imparting stability to a measles antigen. The formulations may be in a form suitable for reconstitution in a physiologically acceptable liquid vehicle to form an injectable solution or suspension for administration to a patient or in the form of dissolvable microneedles or coated microneedles. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10463741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018326041-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018326042-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019015651-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110870913-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022204255-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10722570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10744197-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021252962-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021102369-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11291816-B2 |
| priorityDate |
2013-09-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |